Christina Sallas

Christina Sallas

Auto-generated profile, based on publicly available information

Christina Sallas

Baylor College of Medicine 1 Lester and Sue Smith Breast Center Houston, Texas

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2025 in Cancer Discovery
Verified
Journal Article
Closed access
NNNicholas J. Neill
Nicholas J. Neill
SSShankha Satpathy
Shankha Satpathy
KKKarsten Krug
Karsten Krug
JMJitendra K. Meena
Jitendra K. Meena
NBNivetha Ramesh Babu
Nivetha Ramesh Babu
TWThomas F. Westbrook
Thomas F. Westbrook
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with few effective targeted therapies. Taxanes and other microtubule-targeting agents (MTA) are first-line chemotherapies for TNBC; however, the molecular mechanisms that underlie TNBC taxane sensitivity are largely unknown, preventing selection of taxane-responsive patients and development of more selective therapeutic strategies. In this study, we identified tumor-selective vulnerabilities in TNBC harboring inactivation of the tumor suppressor PTPN12 by integrating proteogenomic characterization and synthetic lethality screening. We discovered that PTPN12 inactivation drives mitotic defects through aberrant hyperactivation of the ubiquitin ligase complex APCFZR1, a critical regulator of the cell cycle. Consistent with the mitotic stress caused by PTPN12 inactivation in TNBC cell lines, tumors harboring loss of PTPN12 exhibit heightened sensitivity to taxane chemotherapy. Collectively, these data suggests that PTPN12 inactivation may drive chromosomal instability and favorable MTA response in TNBC—two prominent features of the disease with unclear mechanistic etiology. Significance: Many TNBCs respond to MTAs, but the underlying cause(s) of this sensitivity remain poorly understood. Herein, we discover that the tumor suppressor PTPN12 regulates mitotic fidelity and MTA sensitivity in a large subset of patients with TNBC, which has significant implications for the use of MTAs in breast cancer.

3 August 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
AHAnh Minh Tran Huynh
Anh Minh Tran Huynh
JLJonathan T. Lei
Jonathan T. Lei
RBRachel Brough
Rachel Brough
CSChristina Sallas
Christina Sallas
JXJun Xu
Jun Xu
MAMeenakshi Anurag
Meenakshi Anurag
Proteogenomic analyses have identified an association between LIG1 (DNA ligase I) loss and chemotherapy resistance in a subset of triple-negative breast cancer (TNBC) enriched for TP53 mutations. In this study, we demonstrate that co-occurrence of TP53 mutations and LIG1 loss is associated with upregulated DNA damage repair (DDR) activity, including homologous recombination (HR), likely contributing to reduced platinum sensitivity. Unbiased genetic and monotherapy drug screens identified poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) as a potential treatment for LIG1-depleted tumors; however, the increase in sensitivity was modest and lower than that observed in TNBC models with HR deficiency. Subsequently, a screen of PARP inhibition in combination with each of 120 clinically relevant DDR inhibitors revealed that PARPi sensitivity in LIG1-loss cells was significantly enhanced by the addition of an ATR inhibitor. Olaparib and ceralasertib demonstrated synergistic cytotoxicity in LIG1-loss cell line models; the combination significantly reduced tumor volume in a LIG1-low patient-derived xenograft (PDX )model compared with either monotherapy and showed greater ex vivo cytotoxicity in a LIG1-low PDX organoid model versus a LIG1-high control. Hence, this study highlights LIG1 status as a stratification factor for ongoing and future clinical trials of DDR-targeted combinations in TNBCs.

3 November 2025
Verified
Other
Open access
PDF file
NNNicholas J. Neill
Nicholas J. Neill
SSShankha Satpathy
Shankha Satpathy
KKKarsten Krug
Karsten Krug
JMJitendra K. Meena
Jitendra K. Meena
NBNivetha Ramesh Babu
Nivetha Ramesh Babu
TWThomas F. Westbrook
Thomas F. Westbrook
Figure S3: PTPN12-deficient cells are vulnerable to perturbation of mitotic regulators (related to Figure 3).

3 November 2025
Verified
Other
Open access
NNNicholas J. Neill
Nicholas J. Neill
SSShankha Satpathy
Shankha Satpathy
KKKarsten Krug
Karsten Krug
JMJitendra K. Meena
Jitendra K. Meena
NBNivetha Ramesh Babu
Nivetha Ramesh Babu
TWThomas F. Westbrook
Thomas F. Westbrook
Table S2: Proteogenomic fold-change data (PTPN12 normal vs deficient) (related to Figure 2).

3 November 2025
Verified
Other
Open access
PDF file
NNNicholas J. Neill
Nicholas J. Neill
SSShankha Satpathy
Shankha Satpathy
KKKarsten Krug
Karsten Krug
JMJitendra K. Meena
Jitendra K. Meena
NBNivetha Ramesh Babu
Nivetha Ramesh Babu
TWThomas F. Westbrook
Thomas F. Westbrook
Figure S5: PTPN12-deficient cells exhibit mitotic defects dependent on APCFZR1 hyperactivation (related to Figure 5).

3 November 2025
Verified
Other
Open access
PDF file
NNNicholas J. Neill
Nicholas J. Neill
SSShankha Satpathy
Shankha Satpathy
KKKarsten Krug
Karsten Krug
JMJitendra K. Meena
Jitendra K. Meena
NBNivetha Ramesh Babu
Nivetha Ramesh Babu
TWThomas F. Westbrook
Thomas F. Westbrook
Figure S1: Integration of proteogenomics and functional genetics to reveal novel vulnerabilities in TNBC (related to Figure 1).